966P - Mutation profiles of nasopharyngeal carcinomas in South-Eastern European patients

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Head and Neck Cancers
Presenter George Fountzilas
Citation Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376
Authors G. Fountzilas1, A. Psyrri1, E. Giannoulatou2, G. Kouvatseas3, D. Rontogianni1, E. Ciuleanu4, T. Ciuleanu5, L. Resiga4, T. Zaramboukas1, M. Bobos1, S. Chrisafi1, E. Tsolaki1, K. Papadopoulou1, K. Markou1, N. Charalambakis1, A. Koutras1, A. Kalogera-Fountzila1, M. Skondra1, D. Pectasides1, V. Kotoula1
  • 1Data Office, Hellenic Cooperative Oncology Group (HeCOG), 11524 - Athens/GR
  • 2Bioinformatics, Victor Chang Cardiac Research Institute, Darlinghurst/AU
  • 3Biostatistics, Health Data Specialists Ltd, Athens/GR
  • 4Radiation, Ion Chiricuta Oncology Institute-IOCN, 400015 - Cluj Napoca/RO
  • 5Medical Oncology, Ion Chiricuta Oncology Institute-IOCN, 400015 - Cluj Napoca/RO



Nasopharyngeal cancer (NPC) is characterized by a remarkable geographical variation and biologic diversity. Importantly, studies investigating mutation profiles of NPC in European populations are scarce.


We investigated the mutational profile of 127 NPC (89% EBV positive) in 93 Greek (GR) and 34 Romanian (RO) patients with locally advanced disease, treated with concomitant chemo-radiotherapy (CCRT) or induction chemotherapy (IC) followed by CCRT. In 19 tumors, dissected matched tumor/lymphocyte (T/L) pairs were compared. Mutation (amino acid changing, minor allele frequency


We identified 1562 mutations in 101/129 tumors (94%). Mutations were mostly found in homologous recombination repair (HRR; 34%), chromatin remodelling (15%) and immune response related (IRR; 10%) genes. In the matched T/L samples, common mutations were identified in 10 cases only, the rest harbouring private mutations. Shared T/L mutations occurred at higher frequencies within the same tumor than T- and L-private mutations (p 


Different genes and sets of genes are affected in stromal and tumor components of NPC, which is important for targeted treatment considerations. Ethnic differences in mutation profiles exist but do not seem to interfere with patient outcome, which seems adversely affected by the absence of EBV and by the presence of BRCA1 mutations.

Clinical trial identification


Legal entity responsible for the study

Hellenic Cooperative Oncology Group


Hellenic Cooperative Oncology Group


G. Fountzilas: Advisory Board: Astra Zeneca S.A. All other authors have declared no conflicts of interest.